Professor Fahri Saatcioglu –heading the research group at the University of Oslo & the Biosciences Department IBV, is currently studying how the male sex hormone – androgens can affect the overall risk of being under the impact of prostate cancer. The research team has been working dedicatedly towards studying the “intracellular signaling pathways” in the prostate cancer cells. This research has been delivering promising results. The scientific article representing the results was published on 24th January in the famous journal “Nature Communications.”
Saatcioglu says, “We think that we have found is quite exciting and promising. We have revealed that a new molecule drug named “MKC8866” has been showing great results on the overall growth of prostate cancer cells – both in animal experts and cell culture. As such, we are planning clinical trials with human beings as well. We are expecting the trials to be carried out in Western Europe and Scandinavia.”
There is no denying the fact that prostate cancer is the most common form of cancer in men in Western countries. Every year, there are approximately 1.1 million cases – all across the world. Given the rising trend of prostate cancer in men all around the world, the overall need for effective treatment is quite urgent.
The molecule drug named “MKC8866” is like a small molecule that belongs to the group of substances referred to as “hydroxyl-aryl-aldehydes.” The molecule drug MKC8866 has been developed by the famous biotech company –MannKind Corporation based in the United States. The research group led by Professor Saatcioglu has documented that the drug MCK8866 is known for counteracting prostate cancer growth. The result shows that it interferes with a specific type of chain reaction – a particular signaling pathway, associated with the stress response of the cells.
The intracellular signaling pathway is central to the new discovery and is linked to the cells’ endoplasmic reticulum. This is a small cell organ – in the form of an organelle, consisting of a network of minute membranes inside the cells. The MCK8866 has been developed for the purpose of providing treatment for prostate cancer in men all across the world. It is known for inhibiting the growth of prostate cancer cells and tumors – both in-vitro and in-vivo, in the mice prostate cancer samples.
HOPE RISE With Us!